TNSN06226A1 - Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases - Google Patents
Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseasesInfo
- Publication number
- TNSN06226A1 TNSN06226A1 TNP2006000226A TNSN06226A TNSN06226A1 TN SN06226 A1 TNSN06226 A1 TN SN06226A1 TN P2006000226 A TNP2006000226 A TN P2006000226A TN SN06226 A TNSN06226 A TN SN06226A TN SN06226 A1 TNSN06226 A1 TN SN06226A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pyrimidin
- pyrazolo
- treatment
- protein kinase
- dependent diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53822004P | 2004-01-22 | 2004-01-22 | |
PCT/EP2005/000602 WO2005070431A1 (en) | 2004-01-22 | 2005-01-21 | Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN06226A1 true TNSN06226A1 (en) | 2007-12-03 |
Family
ID=34807167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2006000226A TNSN06226A1 (en) | 2004-01-22 | 2006-07-21 | Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1708710A1 (ru) |
JP (1) | JP2007519662A (ru) |
KR (1) | KR20070009546A (ru) |
CN (1) | CN1909908A (ru) |
AR (1) | AR049769A1 (ru) |
AU (1) | AU2005205915B2 (ru) |
BR (1) | BRPI0507071A (ru) |
CA (1) | CA2552885A1 (ru) |
EC (1) | ECSP066718A (ru) |
IL (1) | IL176737A0 (ru) |
MA (1) | MA28400B1 (ru) |
NO (1) | NO20063758L (ru) |
PE (1) | PE20051089A1 (ru) |
RU (1) | RU2006130003A (ru) |
TN (1) | TNSN06226A1 (ru) |
TW (1) | TW200528103A (ru) |
WO (1) | WO2005070431A1 (ru) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563798B2 (en) * | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
US7776865B2 (en) | 2005-10-06 | 2010-08-17 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
CN101360499B (zh) * | 2005-10-06 | 2015-10-07 | 默沙东公司 | 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途 |
US8114874B2 (en) | 2005-12-23 | 2012-02-14 | Ariad Pharmaceuticals, Inc. | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
AU2007223865A1 (en) * | 2006-03-08 | 2007-09-13 | Novartis Ag | Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders |
WO2007109183A2 (en) * | 2006-03-20 | 2007-09-27 | Novartis Ag | Mutations and polymorphisms of fms-related tyrosine kinase 1 |
GB0606804D0 (en) * | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic Compounds |
GB0606805D0 (en) * | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
EP2074127A1 (en) * | 2006-09-28 | 2009-07-01 | Novartis AG | Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
EP1918291A1 (en) * | 2006-10-30 | 2008-05-07 | Novartis AG | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators |
WO2008153870A1 (en) * | 2007-06-07 | 2008-12-18 | Schering Corporation | Synthesis of substituted-3-aminopyrazoles |
US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
AU2010300925A1 (en) | 2009-09-30 | 2012-03-29 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
WO2012020726A1 (ja) * | 2010-08-09 | 2012-02-16 | 株式会社ファルマデザイン | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 |
WO2012023143A1 (en) | 2010-08-19 | 2012-02-23 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
US20150038500A1 (en) * | 2011-11-25 | 2015-02-05 | Catholic University Industry-Academic Cooperation Foundation | Pharmaceutical composition for preventing and treating ophthalmic disorders |
CN105906630B (zh) * | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物 |
HUE053067T2 (hu) | 2015-07-16 | 2021-06-28 | Array Biopharma Inc | Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
CN106588893A (zh) * | 2016-12-01 | 2017-04-26 | 北京万全德众医药生物技术有限公司 | 维拉佐酮双氧化物的制备 |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
CN118005640A (zh) * | 2018-01-29 | 2024-05-10 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
CN109836428A (zh) * | 2019-02-27 | 2019-06-04 | 华东师范大学 | 具有免疫抑制活性的吡唑[4,3-d]嘧啶衍生物及用途 |
WO2021007094A1 (en) * | 2019-07-10 | 2021-01-14 | Musc Foundation For Research Development | Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury |
WO2021108408A1 (en) | 2019-11-25 | 2021-06-03 | Amgen Inc. | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
TW202337433A (zh) * | 2022-02-08 | 2023-10-01 | 美商德洛斯股份有限公司 | 用於治療癌症及其他適應症之組成物及方法 |
CN114751910B (zh) * | 2022-05-17 | 2023-02-24 | 重庆文理学院 | 一种可诱导细胞巨泡式死亡的化合物及其制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3130633A1 (de) * | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide |
US5688949A (en) * | 1991-04-22 | 1997-11-18 | Otsuka Pharmaceutical Factory, Inc. | Pyrazolo 1,5-A!pyrimidine derivatives and anti-inflammatory agent containing the same |
CN1046730C (zh) * | 1994-06-21 | 1999-11-24 | 株式会社大塚制药工场 | 吡唑并[1,5-a]嘧啶衍生物 |
JP3163413B2 (ja) * | 1994-06-21 | 2001-05-08 | 株式会社大塚製薬工場 | 鎮痛剤 |
WO1998010590A1 (fr) * | 1996-09-02 | 1998-03-12 | Sony Corporation | Dispositif et procede de transmission d'un signal video |
AR041135A1 (es) * | 2002-09-04 | 2005-05-04 | Schering Corp | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas |
MXPA05002570A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
-
2005
- 2005-01-20 PE PE2005000080A patent/PE20051089A1/es not_active Application Discontinuation
- 2005-01-20 AR ARP050100208A patent/AR049769A1/es unknown
- 2005-01-21 KR KR1020067014683A patent/KR20070009546A/ko not_active Application Discontinuation
- 2005-01-21 BR BRPI0507071-6A patent/BRPI0507071A/pt not_active IP Right Cessation
- 2005-01-21 CN CNA2005800030379A patent/CN1909908A/zh active Pending
- 2005-01-21 EP EP05706961A patent/EP1708710A1/en not_active Withdrawn
- 2005-01-21 AU AU2005205915A patent/AU2005205915B2/en not_active Ceased
- 2005-01-21 CA CA002552885A patent/CA2552885A1/en not_active Abandoned
- 2005-01-21 WO PCT/EP2005/000602 patent/WO2005070431A1/en active Application Filing
- 2005-01-21 JP JP2006550056A patent/JP2007519662A/ja active Pending
- 2005-01-21 TW TW094101852A patent/TW200528103A/zh unknown
- 2005-01-21 RU RU2006130003/15A patent/RU2006130003A/ru not_active Application Discontinuation
-
2006
- 2006-07-06 IL IL176737A patent/IL176737A0/en unknown
- 2006-07-10 MA MA29182A patent/MA28400B1/fr unknown
- 2006-07-21 EC EC2006006718A patent/ECSP066718A/es unknown
- 2006-07-21 TN TNP2006000226A patent/TNSN06226A1/en unknown
- 2006-08-22 NO NO20063758A patent/NO20063758L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2552885A1 (en) | 2005-08-04 |
NO20063758L (no) | 2006-10-23 |
AU2005205915B2 (en) | 2009-05-21 |
JP2007519662A (ja) | 2007-07-19 |
BRPI0507071A (pt) | 2007-06-19 |
ECSP066718A (es) | 2006-10-31 |
RU2006130003A (ru) | 2008-04-10 |
AR049769A1 (es) | 2006-09-06 |
TW200528103A (en) | 2005-09-01 |
MA28400B1 (fr) | 2007-01-02 |
KR20070009546A (ko) | 2007-01-18 |
EP1708710A1 (en) | 2006-10-11 |
PE20051089A1 (es) | 2006-01-25 |
IL176737A0 (en) | 2006-10-31 |
AU2005205915A1 (en) | 2005-08-04 |
WO2005070431A1 (en) | 2005-08-04 |
CN1909908A (zh) | 2007-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN06226A1 (en) | Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases | |
GB0211649D0 (en) | Organic compounds | |
RS20060004A (en) | Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors | |
IL182893A0 (en) | PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
WO2005097135A3 (en) | Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives | |
MY143206A (en) | 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors | |
PL1687305T3 (pl) | Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych | |
WO2003070236A3 (en) | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | |
MY142019A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
GB0330043D0 (en) | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them | |
GB0330042D0 (en) | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them | |
WO2005005414A3 (en) | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
BR0315988A (pt) | Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos | |
MX2007005644A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa. | |
WO2007120752A3 (en) | 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders | |
CA2555262C (en) | 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | |
WO2006110298A3 (en) | 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof | |
PL2004653T3 (pl) | 3-Podstawione N-(arylo- lub heteroarylo)-pirazo[1,5-a]pirymidyny jako inhibitory kinazy | |
WO2005014572A8 (en) | Pyrimidylpyrrole derivatives active as kinase inhibitors | |
MXPA05009719A (es) | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. | |
TW200502236A (en) | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | |
WO2005082884A3 (en) | 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease | |
MXPA05012826A (es) | Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen. |